Literature DB >> 6810288

[Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].

J Grosset, C Truffot, J Fermanian, H Lecoeur.   

Abstract

In a first experiment mice infected intravenously with 10(6) Mycobacterium tuberculosis were randomly treated either with isoniazid (INH) + rifampicin (RMP) 25 mg/kg or with INH + RMP + pyrazinamide (PZA) or with INH + RMP + PZA + streptomycin (SM). The decrease of the viable counts (CFU) in the lungs was similar with all three regimens. In a second experiment, mice were treated for six months either with INH + RMP 25 mg/kg or INH + RMP 10 mg/kg. After a follow-up of six months, mice were killed and their lungs and spleen cultivated. Positive cultures were obtained in 7.5 p. cent of the mice treated with the high dose of RMP and 36.5 p. cent in the mice treated with the low dose (p less than 0.05). A third experiment demonstrated that, during the first two months of treatment, adding PZA to INH + RMP 10 mg/kg increased significantly the overall effectiveness of INH + RMP 10 mg/kg combination. A fourth experiment demonstrated that after three initial months of INH + RMP 10 mg/kg, RMP alone was as effective as RMP + INH or RMP + INH + PZA. It may be concluded that RMP and PZA are both active on the intracellular population of Mycobacterium tuberculosis and that RMP is the only drug to act on persisting Mycobacterium tuberculosis in extracellular lesions.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6810288

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  20 in total

1.  Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.

Authors:  M Ibrahim; K Andries; N Lounis; A Chauffour; C Truffot-Pernot; V Jarlier; N Veziris
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

Review 2.  Dormancy of Mycobacterium tuberculosis and latency of disease.

Authors:  L G Wayne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

3.  Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model.

Authors:  M Brun-Pascaud; P Rajagopalan-Levasseur; F Chau; G Bertrand; L Garry; F Derouin; P M Girard
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?

Authors:  N Lounis; B Ji; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.

Authors:  Jean-Philippe Lanoix; Thomas Ioerger; Aimee Ormond; Firat Kaya; James Sacchettini; Véronique Dartois; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

7.  Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.

Authors:  Zahoor Ahmad; Sandeep Tyagi; Austin Minkowski; Charles A Peloquin; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2013-07-01       Impact factor: 21.405

8.  Anticytomegaloviral activity of methotrexate associated with preferential accumulation of drug by cytomegalovirus-infected cells.

Authors:  M Wachsman; F M Hamzeh; H Saito; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice?

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

10.  In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.

Authors:  B JI; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.